Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP978417.RAV75uBkYcoxBpeQiNhr5U_kl0lEStGta9KWdHdVxBEMI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP978417.RAV75uBkYcoxBpeQiNhr5U_kl0lEStGta9KWdHdVxBEMI130_assertion type Assertion NP978417.RAV75uBkYcoxBpeQiNhr5U_kl0lEStGta9KWdHdVxBEMI130_head.
- NP978417.RAV75uBkYcoxBpeQiNhr5U_kl0lEStGta9KWdHdVxBEMI130_assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP978417.RAV75uBkYcoxBpeQiNhr5U_kl0lEStGta9KWdHdVxBEMI130_provenance.
- NP978417.RAV75uBkYcoxBpeQiNhr5U_kl0lEStGta9KWdHdVxBEMI130_assertion evidence source_evidence_literature NP978417.RAV75uBkYcoxBpeQiNhr5U_kl0lEStGta9KWdHdVxBEMI130_provenance.
- NP978417.RAV75uBkYcoxBpeQiNhr5U_kl0lEStGta9KWdHdVxBEMI130_assertion SIO_000772 10883674 NP978417.RAV75uBkYcoxBpeQiNhr5U_kl0lEStGta9KWdHdVxBEMI130_provenance.
- NP978417.RAV75uBkYcoxBpeQiNhr5U_kl0lEStGta9KWdHdVxBEMI130_assertion wasDerivedFrom befree-20150227 NP978417.RAV75uBkYcoxBpeQiNhr5U_kl0lEStGta9KWdHdVxBEMI130_provenance.
- NP978417.RAV75uBkYcoxBpeQiNhr5U_kl0lEStGta9KWdHdVxBEMI130_assertion wasGeneratedBy ECO_0000203 NP978417.RAV75uBkYcoxBpeQiNhr5U_kl0lEStGta9KWdHdVxBEMI130_provenance.